Department of Public Health, University of Naples Federico II, 80131, Naples, Italy.
U.O.C. of Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy.
Crit Rev Oncol Hematol. 2021 Apr;160:103300. doi: 10.1016/j.critrevonc.2021.103300. Epub 2021 Mar 17.
Since their discovery, relevant efforts have been made to optimize the detection approaches to EGFR mutations as well as the clinical management of EGFR-mutated NSCLC. The recent shift from single gene testing to novel comprehensive detection platforms along with the development of new generation tyrosine kinase inhibitors, targeting both common and uncommon EGFR-mutations, is leading to a progressive increase in the number of patients who may benefit from targeted approaches, with subsequent impact on their long-term survival and quality of life. However, a prompt and adequate implementation of the most recent diagnostic and treatment advances in the routine practice often remains critical to be specifically addressed. In this review we provide a complete and updated overview of the different detection platforms and therapeutic options currently available for the clinical management of advanced EGFR-positive NSCLC, summarizing scientific evidence and describing molecular testing as well as treatment practice in the real-word scenario.
自发现以来，人们一直致力于优化 EGFR 突变的检测方法以及 EGFR 突变型 NSCLC 的临床管理。最近，从单一基因检测到新型综合检测平台的转变，以及针对常见和不常见 EGFR 突变的新一代酪氨酸激酶抑制剂的发展，导致可能受益于靶向治疗的患者数量不断增加，从而对他们的长期生存和生活质量产生影响。然而，在常规实践中及时、充分地实施最新的诊断和治疗进展仍然是需要特别关注的关键问题。在这篇综述中，我们全面、及时地概述了目前可用于晚期 EGFR 阳性 NSCLC 临床管理的不同检测平台和治疗选择，总结了科学证据，并描述了实际情况下的分子检测和治疗实践。
